BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2026-09
221 industry Phase 2/3 trial readout(s) and 38 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09 est. | P2/P3 | Medeor Therapeutics, Inc. | NCT03605654 Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants | Kidney Transplant Rejection | withdrawn | |
| 2026-09 est. | P2 | Karyopharm Therapeutics Inc KPTIQ | NCT04562870 A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | Myelofibrosis | active not recruiting | 112 |
| 2026-09 est. | P1/P2 | Clarity Pharmaceuticals Ltd | NCT04868604 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) | Prostatic Neoplasms, Castration-Resistant | recruiting | 54 |
| 2026-09 est. | P3 | Eidos Therapeutics, a BridgeBio company | NCT04882735 Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | withdrawn | |
| 2026-09 est. | P2 | Vasomune Therapeutics, Inc. | NCT05123755 Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia. | Acute Respiratory Distress Syndrome; Viral or Bacterial Infections; Pneumonia; Pneumonia, Viral; Res | active not recruiting | 60 |
| 2026-09 est. | P3 | Salutaris Medical Devices, Inc. | NCT05251636 Adjunct Episcleral Brachytherapy for PCV | Age-Related Macular Degeneration; Polypoid Choroidal Vasculopathy | not yet recruiting | 159 |
| 2026-09 est. | P3 | Alkermes, Inc. ALKS | NCT05303064 Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder | Schizophrenia; Bipolar I Disorder | recruiting | 220 |
| 2026-09 est. | P1/P2 | Silence Therapeutics plc SLN | NCT05499013 Study to Assess SLN124 in Patients With Polycythemia Vera | Polycythemia Vera | active not recruiting | 69 |
| 2026-09 est. | P2/P3 | REGENXBIO Inc. RGNX | NCT05693142 AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | active not recruiting | 65 |
| 2026-09 est. | P3 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | NCT05717764 Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic | Recurrent Metastatic Nasopharyngeal Carcinoma | not yet recruiting | 500 |
| 2026-09 est. | P1/P2 | Shanghai HyaMab Biotech Co.,Ltd. | NCT05801237 PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor | Locally Advanced/Metastatic Solid Tumors | recruiting | 120 |
| 2026-09 est. | P1/P2 | Coordination Pharmaceuticals, Inc. | NCT05838729 Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer | Head Neck Cancer; Intratumoral Injection | recruiting | 16 |
| 2026-09 est. | P2 | Repurposed Therapeutics, Inc. | NCT05852730 Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance | Motion Sickness, Space; Motion Simulation; Parabolic Flight | unknown | 80 |
| 2026-09 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05978284 Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | Small Cell Lung Cancer; Neuroendocrine Carcinoma | recruiting | 54 |
| 2026-09 est. | P1/P2 | Hexaell Biotech Co., Ltd. | NCT05989958 The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure | Acute on Chronic Hepatic Failure; Liver Failure; Hepatitis | recruiting | 92 |
| 2026-09 est. | P1/P2 | Georgiamune Inc | NCT06028074 Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies | Advanced Solid Malignancies | recruiting | 111 |
| 2026-09 est. | P3 | Clarity Pharmaceuticals Ltd | NCT06056830 Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | Prostate Cancer; Prostatic Neoplasms | recruiting | 383 |
| 2026-09 est. | P2 | Tourmaline Bio, Inc., a Novartis Company | NCT06088979 A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease | Thyroid Eye Disease | active not recruiting | 79 |
| 2026-09 est. | P2 | Galmed Pharmaceuticals Ltd | NCT06095986 A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | withdrawn | |
| 2026-09 est. | P3 | AbbVie ABBV | NCT06100744 A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Recei | Juvenile Psoriatic Arthritis | recruiting | 40 |
| 2026-09 est. | P2/P3 | Bio-Thera Solutions | NCT06123884 BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | Cervical Cancer | recruiting | 526 |
| 2026-09 est. | P3 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06196736 A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer | Advanced Urothelial Carcinoma | recruiting | 432 |
| 2026-09 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06452693 A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B | Hepatitis B, Chronic | unknown | 162 |
| 2026-09 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06469879 A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients | Small Cell Lung Cancer Limited Stage | unknown | 358 |
| 2026-09 est. | P3 | Rophibio, Inc. | NCT06470373 A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration | Neovascular Age-related Macular Degeneration (nAMD) | not yet recruiting | 434 |
| 2026-09 est. | P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT06558227 Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | unknown | 90 |
| 2026-09 est. | P3 | argenx ARGX | NCT06742190 A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy | Multifocal Motor Neuropathy (MMN); MMN | active not recruiting | 154 |
| 2026-09 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06767800 A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advan | Gastroesophageal Adenocarcinoma | recruiting | 204 |
| 2026-09 est. | P2 | Cytokinetics CYTK | NCT06793371 AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | recruiting | 60 |
| 2026-09 est. | P2 | Maze Therapeutics MAZE | NCT06830629 A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease | Proteinuric Kidney Disease | recruiting | 74 |
| 2026-09 est. | P3 | Jiangsu BioJeTay Biotechnology Co., Ltd. | NCT06922045 Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients | Hemophilia | active not recruiting | 40 |
| 2026-09 est. | P1/P2 | Jiangsu BioJeTay Biotechnology Co., Ltd. | NCT06929299 A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP) | Primary Immune Thrombocytopenia (ITP) | recruiting | 56 |
| 2026-09 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT06949761 A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced So | Solid Tumor | not yet recruiting | 240 |
| 2026-09 est. | P1/P2 | TYK Medicines, Inc | NCT06950086 Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors | HR-positive, HER2-negative Advanced Breast Cancer | recruiting | 180 |
| 2026-09 est. | P2 | Nanjing Chia-tai Tianqing Pharmaceutical | NCT06982040 Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy | Primary IgA Nephropathy | not yet recruiting | 80 |
| 2026-09 est. | P2 | NewAmsterdam Pharma NAMS | NCT06982508 Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers | Antioxidant Absorption | recruiting | 100 |
| 2026-09 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT06994507 GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer | Chemotherapy-induced Peripheral Neuropathy (CIPN) | recruiting | 352 |
| 2026-09 est. | P3 | Shandong Suncadia Medicine Co., Ltd. | NCT07021976 A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic Cardiomyopathy | active not recruiting | 228 |
| 2026-09 est. | P2 | EIP Pharma Inc | NCT07033481 Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | active not recruiting | 20 |
| 2026-09 est. | P3 | ScandiBio Therapeutics AB | NCT07062198 Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease | Alzheimer Disease | recruiting | 845 |
| 2026-09 est. | P2 | Vanda Pharmaceuticals VNDA | NCT07065773 Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis | Onychomycosis of Toenail | active not recruiting | 50 |
| 2026-09 est. | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT07100418 A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia | Hyperlipidemia | active not recruiting | 224 |
| 2026-09 est. | P2 | Vanda Pharmaceuticals VNDA | NCT07179055 An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye | Dry Eye | recruiting | 160 |
| 2026-09 est. | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT07211542 A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis | recruiting | 75 |
| 2026-09 est. | P1/P2 | Corcept Therapeutics CORT | NCT07276373 Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies | Neoplasms | recruiting | 50 |
| 2026-09 est. | P2 | Biohaven Therapeutics Ltd. BHVN | NCT07281495 Taldefgrobep Alfa in Adults With Overweight and Obesity | Obesity; Overweight | active not recruiting | 150 |
| 2026-09 est. | P2 | Sinovac Life Sciences Co., Ltd. | NCT07300644 Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years | Pneumococcal Infectious Disease | recruiting | 420 |
| 2026-09 est. | P2 | Sichuan Purity Pharmaceutical Technology Co., Ltd. | NCT07304518 Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults | Migraine | recruiting | 456 |
| 2026-09 est. | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT07318103 Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention | Fluid Retention Caused by Heart Failure | recruiting | 153 |
| 2026-09 est. | P2 | Glaukos Corporation GKOS | NCT07400965 Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis | Demodex Blepharitis | recruiting | 250 |
| 2026-09 est. | P1/P2 | Moogene Medi Co., Ltd | NCT07490327 Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia | Androgenetic Alopecia | not yet recruiting | 30 |
| 2026-09 est. | P2 | R-Pharm International, LLC | NCT07517575 Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis | recruiting | 71 |
| 2026-09 est. | P3 | Colgate Palmolive CL | NCT07664592 Comparative Efficacy of Different Dentin Occluding Toothpaste Technologies | Dentinal Sensitivity; Dentinal Hypersensitivity | recruiting | 132 |
| 2026-09 est. | P2 | Shanghai Minwei Biotechnology Co., Ltd | NCT07804797 Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity | Overweight , Obesity | active not recruiting | 71 |
| 2026-09-01 est. | P3 | Incyte Corporation INCY | NCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | Diffuse Large B-cell Lymphoma | active not recruiting | 899 |
| 2026-09-01 est. | P2 | Beijing Continent Pharmaceutical Co, Ltd. | NCT05689645 F573 for Injection for the Treatment of Liver Injury/Failure | Acute Liver Failure; Acute-On-Chronic Liver Failure | recruiting | 97 |
| 2026-09-01 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT05990452 Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 261 |
| 2026-09-01 | P3 | UCB BIOSCIENCES, Inc. | NCT06118255 A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrom | Dravet Syndrome | completed | 25 |
| 2026-09-01 est. | P2 | MedRegen LLC | NCT06307522 MRG-001 in Patients With Alcoholic Hepatitis | Alcoholic Hepatitis; Acute Alcoholic Hepatitis | not yet recruiting | 32 |
| 2026-09-01 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06569056 A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis | Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) | completed | 579 |
| 2026-09-01 est. | P3 | Daewoong Pharmaceutical Co. LTD. | NCT06606093 Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients | Type 2 Diabetic Nephropathy | not yet recruiting | 348 |
| 2026-09-01 est. | P2 | Novo Nordisk A/S NVO | NCT06717698 A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Chronic Kidney Disease | recruiting | 465 |
| 2026-09-01 est. | P2 | Tarian Pharma | NCT06818058 TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis | EGFR Inhibitor-associated Rash | recruiting | 60 |
| 2026-09-01 est. | P1/P2 | Zhejiang Teruisi Pharmaceutical Inc. | NCT07035379 A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCL | Diffuse Large B-Cell Lymphoma (DLBCL) | not yet recruiting | 66 |
| 2026-09-01 | P2 | Ethris GmbH | NCT07059767 Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge | Asthma (Diagnosis) | completed | 50 |
| 2026-09-01 est. | P1/P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07169994 A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | Advanced Solid Tumors; Breast Cancer; Non Small Cell Lung Cancer | recruiting | 414 |
| 2026-09-02 | P2 | Il-Yang Pharm. Co., Ltd. | NCT04691661 Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease | Parkinson Disease | active not recruiting | 43 |
| 2026-09-02 | P3 | Kodiak Sciences Inc KOD | NCT06556368 A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-re | Wet Age-related Macular Degeneration | active not recruiting | 667 |
| 2026-09-02 | P1/P2 | SERDA bv | NCT06628037 SN514-066b Enzyme in Deep Partial Thickness Burns | Burn Injury | terminated | 13 |
| 2026-09-02 est. | P2 | Suzhou Alphamab Co., Ltd. | NCT06747416 KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors | Hemophilia a and B | not yet recruiting | 24 |
| 2026-09-03 | P1/P2 | Nacuity Pharmaceuticals, Inc. | NCT05026632 NPI-002 Intravitreal Implant for the Delay of Cataract Progression | Cataract | completed | 24 |
| 2026-09-03 | P3 | Novartis Pharmaceuticals NVS | NCT05132075 Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | Non-Small Cell Lung Cancer | terminated | 95 |
| 2026-09-03 | P3 | Novo Nordisk A/S NVO | NCT05636176 A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | Heart Failure | terminated | 4874 |
| 2026-09-03 | P2 | Hoffmann-La Roche | NCT06965413 A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants W | Obesity; Overweight; Overweight With One Weight Related Comorbidity | active not recruiting | 285 |
| 2026-09-03 | P3 | AbbVie ABBV | NCT07032597 A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants | Mid Face Volume Deficit | completed | 252 |
| 2026-09-03 | P2 | AstraZeneca AZN | NCT07218900 A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Par | Dyslipidaemia | completed | 76 |
| 2026-09-04 | P3 | Vanda Pharmaceuticals VNDA | NCT04652882 Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) | Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders | completed | 43 |
| 2026-09-04 | P2 | Sanofi SNY | NCT05039840 Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | active not recruiting | 109 |
| 2026-09-04 | P3 | Cybin IRL Limited | NCT06564818 "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Major Depressive Disorder | completed | 223 |
| 2026-09-04 | P3 | GlaxoSmithKline | NCT07596173 A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged | Diphtheria-Tetanus-acellular Pertussis Vaccines | completed | 90 |
| 2026-09-05 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT06730750 A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | Advanced Solid Tumors | active not recruiting | 360 |
| 2026-09-06 est. | P2 | CastleVax Inc. | NCT07215520 Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults | COVID-19 | active not recruiting | 200 |
| 2026-09-07 | P3 | Sarepta Therapeutics, Inc. SRPT | NCT03992430 A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) | Muscular Dystrophy, Duchenne | completed | 160 |
| 2026-09-07 | P2 | Edgewise Therapeutics, Inc. EWTX | NCT05291091 Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | Becker Muscular Dystrophy | completed | 244 |
| 2026-09-07 | P2 | Arcus Biosciences, Inc. RCUS | NCT05329766 A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancie | Gastrointestinal Tract Malignancies | completed | 332 |
| 2026-09-07 | P2 | Merck Sharp & Dohme LLC MRK | NCT07176390 A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) | Arthritis, Rheumatoid | active not recruiting | 185 |
| 2026-09-08 | P3 | Alfasigma S.p.A. | NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis | Ulcerative Colitis | completed | 1173 |
| 2026-09-08 | P1/P2 | BlueSphere Bio, Inc | NCT06704152 BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | AML, Adult Recurrent; ALL, Recurrent, Adult; MDS | terminated | 2 |
| 2026-09-08 | P3 | Disc Medicine, Inc IRON | NCT06910358 Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP) | completed | 183 |
| 2026-09-08 est. | P3 | Medprin Regenerative Medical Technologies Co., Ltd. | NCT07830797 Absorbable Hemostatic Fluid Gelatin Trial | Surgical Bleeding | not yet recruiting | 324 |
| 2026-09-09 | P2 | Gossamer Bio USA, Inc. GOSS | NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | terminated | 74 |
| 2026-09-09 | P2 | HB BioTech, LLC | NCT06483789 Efficacy and Safety of HB-1 for Panic Disorder | Panic Disorder; Mental Illness | terminated | 170 |
| 2026-09-09 | P3 | EyePoint Pharmaceuticals, Inc. EYPT | NCT06683742 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | Wet Age Related Macular Degeneration; wAMD | active not recruiting | 400 |
| 2026-09-09 | P2 | ViiV Healthcare | NCT06741397 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Do | HIV Infections | active not recruiting | 229 |
| 2026-09-09 | P1/P2 | BioInvent International AB | NCT06784648 Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | Melanoma Metastatic; Melanoma of Skin; Melanoma BRAF V600E/K Mutated; Melanoma Recurrent; Melanoma S | active not recruiting | 35 |
| 2026-09-09 | P2 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | NCT07169942 Aleniglipron Phase 2 Body Composition Study | Obesity, Overweight, or Chronic Weight Management | completed | 71 |
| 2026-09-09 | P2 | Kynexis B.V. | NCT07191483 A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia | Cognitive Impairment Associated With Schizophrenia (CIAS) | completed | 149 |
| 2026-09-09 | P1/P2 | Umecrine Cognition AB | NCT07304843 A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive | Primary Biliary Cholangitis (PBC) | completed | 207 |
| 2026-09-10 est. | P3 | Galaxy Therapeutics INC GLXY | NCT05831202 SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial | Intracranial Aneurysm | active not recruiting | 279 |
| 2026-09-10 | P2 | GlaxoSmithKline | NCT06062420 A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of | Neoplasms, Head and Neck | active not recruiting | 316 |
| 2026-09-10 | P1/P2 | Pfizer PFE | NCT06125522 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-S | Breast Cancer | terminated | 11 |
| 2026-09-10 | P3 | Sanofi SNY | NCT06208306 A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD | Chronic Obstructive Pulmonary Disease | completed | 669 |
| 2026-09-10 est. | P1/P2 | Shanghai Vitalgen BioPharma Co., Ltd. | NCT06480461 A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease | Parkinson's Disease | active not recruiting | 39 |
| 2026-09-10 est. | P3 | GlaxoSmithKline | NCT06855160 A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intram | Chickenpox | recruiting | 911 |
| 2026-09-11 est. | P3 | Priovant Therapeutics, Inc. | NCT06431373 A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis | Uveitis, Posterior; Uveitis, Intermediate; Uveitis | active not recruiting | 371 |
| 2026-09-11 | P3 | Guangzhou Gloria Biosciences Co., Ltd. | NCT06514508 Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients | Multiple Myeloma | recruiting | 60 |
| 2026-09-11 | P2 | Phathom Pharmaceuticals, Inc. PHAT | NCT06851559 A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks | Eosinophilic Esophagitis | active not recruiting | 95 |
| 2026-09-11 | P2 | Verdiva Bio Dev Limited | NCT07553299 A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity; Overweight; Weight Maintenance | terminated | 8 |
| 2026-09-14 | P3 | Genzyme, a Sanofi Company | NCT03754790 Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | Hemophilia | completed | 281 |
| 2026-09-14 | P1/P2 | Cocrystal Pharma, Inc. COCP | NCT07198139 A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus | Norovirus | completed | 32 |
| 2026-09-15 | P1/P2 | Bayer | NCT03588299 Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy | Hemophilia A | completed | 11 |
| 2026-09-15 est. | P1/P2 | Wuhan YZY Biopharma Co., Ltd. | NCT05543330 A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC | Malignant Pleural Effusions; NSCLC Stage IV | recruiting | 116 |
| 2026-09-15 | P2 | OM Pharma SA | NCT05857930 A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing | Recurrent Wheezing; Wheezing Lower Respiratory Illness | completed | 296 |
| 2026-09-15 est. | P2 | Thirty Respiratory Limited | NCT07073638 Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis | Pulmonary Tuberculoses | recruiting | 24 |
| 2026-09-15 est. | P2 | Estar Medical dba Medical Technologies, LTD | NCT07318792 Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds | Wound Chronic Draining; Wound Closure | not yet recruiting | 16 |
| 2026-09-15 | P2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07835971 A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension | Hypertension | active not recruiting | 319 |
| 2026-09-16 | P1/P2 | Cellectis S.A. CLLS | NCT04150497 Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | B-cell Acute Lymphoblastic Leukemia | active not recruiting | 45 |
| 2026-09-16 | P2 | BioMarin Pharmaceutical BMRN | NCT06668805 A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Noonan Syndrome | terminated | 18 |
| 2026-09-16 | P2 | TBF Genie Tissulaire | NCT06723782 Surgical Release of Hand Tendons With Wrapping of the Released Tendon Using an Amniotic Membrane | Tendon Adhesion; Tenolysis | completed | 18 |
| 2026-09-16 | P2 | Definium Therapeutics US, Inc. DFTX | NCT07303907 A Phase 2A Trial of DT402 for Autism Spectrum Disorder | Autism Spectrum Disorder; ASD | completed | 5 |
| 2026-09-17 | P2 | Arcus Biosciences, Inc. RCUS | NCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Can | completed | 169 |
| 2026-09-17 | P2 | Tiziana Life Sciences LTD TLSA | NCT06292923 A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients | Secondary Progressive Multiple Sclerosis | completed | 54 |
| 2026-09-17 est. | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT06832410 An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | Type 1 Diabetes; Kidney Transplant | recruiting | 10 |
| 2026-09-17 | P2 | Novartis Pharmaceuticals NVS | NCT06857955 A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients | Hypertension | active not recruiting | 396 |
| 2026-09-17 | P2 | Hoffmann-La Roche | NCT07074886 A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) | Multiple Sclerosis | active not recruiting | 193 |
| 2026-09-17 | P3 | Sarfez Pharmaceuticals, Inc. | NCT07223502 A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hyp | Hypertension (HTN) | withdrawn | |
| 2026-09-17 | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT07233070 HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke. | Acute Ischemic Stroke | completed | 210 |
| 2026-09-17 | P3 | Vaxcyte, Inc. PCVX | NCT07284654 Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 | Pneumococcal Disease | completed | 4049 |
| 2026-09-18 | P3 | Gan & Lee Pharmaceuticals. | NCT06778967 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus (T2DM) | completed | 1133 |
| 2026-09-18 | P2 | Zura Bio Inc ZURA | NCT06993610 Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense | Hidradenitis Suppurativa (HS) | active not recruiting | 247 |
| 2026-09-18 | P2 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | NCT07400588 Aleniglipron Phase 2 in Type 2 Diabetes Mellitus | Obese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Loss | completed | 58 |
| 2026-09-20 est. | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07279194 Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes | Obesity & Overweight | recruiting | 825 |
| 2026-09-20 est. | P2/P3 | Bharat Biotech International Limited | NCT07555392 A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age. | Active Immunisation for Chikungunya Virus Infection | recruiting | 1000 |
| 2026-09-21 est. | P3 | Cardiol Therapeutics Inc. CRDL | NCT06708299 CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) | Recurrent Pericarditis | recruiting | 110 |
| 2026-09-21 | P3 | AstraZeneca AZN | NCT06750289 Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated | Eosinophilic Asthma | completed | 130 |
| 2026-09-21 | P2 | Aclaris Therapeutics, Inc. ACRS | NCT07011706 ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis; Atopic; Dermatitis; AD; Eczema | active not recruiting | 110 |
| 2026-09-22 | P3 | Takeda TAK | NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | 354 |
| 2026-09-22 est. | P1/P2 | ImmVira Pharma Co. Ltd | NCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Me | Solid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLC | recruiting | 30 |
| 2026-09-22 | P1/P2 | Tango Therapeutics, Inc. TNGX | NCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer; Lung Adenocarcinoma | active not recruiting | 126 |
| 2026-09-22 | P2 | BeOne Medicines ONC | NCT05952037 A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglo | Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobuli | active not recruiting | 114 |
| 2026-09-22 | P2 | Sanofi SNY | NCT06033833 Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Prev | Asthma | terminated | 335 |
| 2026-09-22 | P2/P3 | Actinogen Medical | NCT06125951 Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease | Dementia Moderate; Dementia, Mild; Alzheimer Disease | active not recruiting | 247 |
| 2026-09-22 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06841731 A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia | Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP) | completed | 120 |
| 2026-09-22 | P2 | Vera Therapeutics, Inc. VERA | NCT07020923 Monthly Dosing of Atacicept in IgAN | IgA Nephropathy (IgAN); Berger Disease | active not recruiting | 90 |
| 2026-09-22 | P3 | Gan & Lee Pharmaceuticals. | NCT07292441 Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss | Overweight or Obesity | completed | 224 |
| 2026-09-22 | P3 | BioNTech SE BNTX | NCT07300839 A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age | COVID-19; SARS-COV-2 Infection | completed | 5240 |
| 2026-09-22 | P2 | Samsung Bioepis Co., Ltd. | NCT07844343 A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema | Neovascular Age-related Macular Degeneration; Macular Oedema Secondary to RVO; Diabetic Macular Oede | completed | 33 |
| 2026-09-23 | P2 | Pfizer PFE | NCT05070845 Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | terminated | 61 |
| 2026-09-23 | P2 | Uniquity One (UNI) | NCT06496620 A Study to Evaluate Solrikitug in Participants With COPD (ZION) | COPD | active not recruiting | 182 |
| 2026-09-23 | P2 | Zenas BioPharma (USA), LLC ZBIO | NCT06559163 A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | active not recruiting | 190 |
| 2026-09-23 est. | P1/P2 | Sinocelltech Ltd. | NCT06672536 Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD | nAMD | recruiting | 82 |
| 2026-09-23 | P3 | CSL Behring | NCT06738485 Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products | Congenital Hemophilia A | completed | 62 |
| 2026-09-23 | P3 | Sanofi SNY | NCT06834347 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusi | Chronic Rhinosinusitis With Nasal Polyps | active not recruiting | 231 |
| 2026-09-23 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06937749 A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH) | active not recruiting | 181 |
| 2026-09-23 | P2 | EIP Pharma Inc | NCT06987643 A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke | Moderate to Severe Acute Ischaemic Stroke; Ischaemic Stroke | completed | 45 |
| 2026-09-23 | P2 | Jiangsu Simcere Pharmaceutical Co., Ltd. | NCT07175233 A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis (AD) | active not recruiting | 184 |
| 2026-09-24 | P1/P2 | Novartis Pharmaceuticals NVS | NCT05798117 An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus | Systemic Lupus Erythematosus; Lupus Nephritis | completed | 21 |
| 2026-09-24 | P2 | Ribocure Pharmaceuticals AB | NCT06649266 Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D | Chronic Hepatitis D | active not recruiting | 14 |
| 2026-09-24 | P3 | Sanofi SNY | NCT06834360 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusi | Chronic Rhinosinusitis With Nasal Polyps | active not recruiting | 216 |
| 2026-09-24 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06862908 A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity | Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced E | active not recruiting | 141 |
| 2026-09-24 | P2 | CuraSen Therapeutics, Inc. | NCT07089043 A Study in Subjects With Neurogenic Orthostatic Hypotension | Neurogenic Orthostatic Hypotension | active not recruiting | 12 |
| 2026-09-25 | P2 | Changchun BCHT Biotechnology Co. | NCT07894055 A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) | Pertussis (Whooping Cough); Diphtheria; Tetanus | recruiting | 420 |
| 2026-09-26 est. | P2 | AstraZeneca AZN | NCT06942910 A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and | Chronic Kidney Disease With High Proteinuria | active not recruiting | 224 |
| 2026-09-27 est. | P3 | Biogen BIIB | NCT04961567 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythe | Lupus Erythematosus, Systemic | active not recruiting | 562 |
| 2026-09-27 est. | P1/P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT06864507 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic | Chronic Spontaneous Urticaria | not yet recruiting | 150 |
| 2026-09-28 | P3 | Regeneron Pharmaceuticals REGN | NCT05133531 A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH | Paroxysmal Nocturnal Hemoglobinuria | completed | 202 |
| 2026-09-28 | P1/P2 | Novartis Pharmaceuticals NVS | NCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-S | terminated | 74 |
| 2026-09-28 est. | P3 | Bristol-Myers Squibb BMY | NCT05552976 A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relaps | Relapsed or Refractory Multiple Myeloma | active not recruiting | 606 |
| 2026-09-28 | P2 | Incyte Corporation INCY | NCT05888844 A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | terminated | 63 |
| 2026-09-28 est. | P2 | Attralus, Inc. | NCT05951049 A Study of AT-02 in Subjects With Systemic Amyloidosis. | Amyloidosis; Systemic | active not recruiting | 120 |
| 2026-09-28 est. | P2/P3 | Ocugen OCGN | NCT05956626 A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease | Stargardt Disease | active not recruiting | 51 |
| 2026-09-28 | P3 | Chongqing Peg-Bio Biopharm Co., Ltd. | NCT06512584 Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition | Short Bowel Syndrome | active not recruiting | 72 |
| 2026-09-28 | P3 | Incyte Corporation INCY | NCT06516965 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | Prurigo Nodularis | active not recruiting | 346 |
| 2026-09-28 | P3 | MoonLake Immunotherapeutics AG MLTX | NCT06768671 An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurat | Hidradenitis Suppurativa | completed | 35 |
| 2026-09-28 | P3 | Cinclus Pharma Holding AB | NCT07037875 A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disea | GERD (Gastroesophageal Reflux Disease) | completed | 523 |
| 2026-09-29 | P1/P2 | Takeda TAK | NCT02716116 A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | completed | 324 |
| 2026-09-29 | P3 | Inventiva Pharma IVA | NCT04849728 A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 an | NASH - Nonalcoholic Steatohepatitis | active not recruiting | 1000 |
| 2026-09-29 | P1/P2 | Pfizer PFE | NCT06924320 A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes | Obesity and Obesity-related Medical Conditions | completed | 201 |
| 2026-09-29 | P2 | Sanofi SNY | NCT07222189 A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-L | Colitis Ulcerative; Crohn's Disease | terminated | 7 |
| 2026-09-30 est. | P1/P2 | ImmunityBio, Inc. IBRX | NCT02138734 A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Non-muscle Invasive Bladder Cancer | active not recruiting | 369 |
| 2026-09-30 est. | P2/P3 | SyneuRx International (Taiwan) Corp | NCT03094429 An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an A | Refractory Schizophrenia | recruiting | 287 |
| 2026-09-30 est. | P1/P2 | Turning Point Therapeutics, Inc. TPB | NCT04094610 A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Locally Advanced Solid Tumors; Metastatic Solid Tumors; Lymphoma; Primary CNS Tumors | recruiting | 75 |
| 2026-09-30 | P3 | GlaxoSmithKline | NCT04167358 Linerixibat Long-term Safety, and Tolerability Study | Cholestasis | completed | 242 |
| 2026-09-30 est. | P3 | Hoffmann-La Roche | NCT04603807 A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) Wit | Carcinoma, Non-Small-Cell Lung | active not recruiting | 217 |
| 2026-09-30 est. | P3 | Biogen BIIB | NCT04895241 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythe | Lupus Erythematosus, Systemic | active not recruiting | 548 |
| 2026-09-30 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer | Non-Small Cell Lung Cancer | active not recruiting | 506 |
| 2026-09-30 est. | P3 | Beijing Continent Pharmaceutical Co, Ltd. | NCT05288179 Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis | Pneumoconiosis | recruiting | 272 |
| 2026-09-30 | P3 | Supergene, LLC | NCT05372718 Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial | Acute Limb Ischemia | completed | 170 |
| 2026-09-30 est. | P1/P2 | J Ints Bio | NCT05394831 A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC | EGFR Mutant Advanced Non-small Cell Lung Cancer | recruiting | 150 |
| 2026-09-30 est. | P3 | AstraZeneca AZN | NCT05557838 Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC | Hepatocellular Carcinoma | active not recruiting | 214 |
| 2026-09-30 est. | P2 | Mirati Therapeutics Inc. | NCT05609578 Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Advanced NSCLC; Metastatic Lung Cancer | active not recruiting | 90 |
| 2026-09-30 est. | P1/P2 | H. Lundbeck A/S | NCT05669950 A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia | recruiting | 42 |
| 2026-09-30 | P2 | Incyte Corporation INCY | NCT05879822 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Advanced Solid Tumor | terminated | 73 |
| 2026-09-30 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT05888831 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | Advanced Solid Tumors | active not recruiting | 100 |
| 2026-09-30 est. | P2 | Cantex Pharmaceuticals | NCT05986851 Azeliragon in MGMT Unmethylated Glioblastoma | Glioblastoma | active not recruiting | 30 |
| 2026-09-30 est. | P3 | Beijing Pearl Biotechnology Limited Liability Company | NCT05989542 A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) | Non-small Cell Lung Cancer | recruiting | 136 |
| 2026-09-30 est. | P1/P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT06214156 A Clinical Study of T3011 in Subjects With Advanced Melanoma | Advanced Melanoma | recruiting | 42 |
| 2026-09-30 est. | P2 | Stamford Pharmaceuticals, Inc. | NCT06344052 To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma | Basal Cell Carcinoma | recruiting | 80 |
| 2026-09-30 est. | P2 | Convalife (Shanghai) Co., Ltd. | NCT06374888 Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With | Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metasta | not yet recruiting | 28 |
| 2026-09-30 | P2 | Inozyme Pharma | NCT06462547 ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency | Gene Mutations; Pseudoxanthoma Elasticum; Arterial Calcification; Ectonucleotide Pyrophosphatase/pho | terminated | 22 |
| 2026-09-30 est. | P3 | GlaxoSmithKline | NCT06534892 An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age | Respiratory Syncytial Virus Infections | active not recruiting | 10212 |
| 2026-09-30 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT06637423 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) | Non-Muscle Invasive Bladder Cancer | completed | 35 |
| 2026-09-30 est. | P3 | Shanghai JMT-Bio Inc. | NCT06735391 A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non | Locally Advanced or Metastatic Non-squamous NSCLC; Harboring EGFR Sensitive Mutations NSCLC; Previou | recruiting | 516 |
| 2026-09-30 est. | P2/P3 | Chongqing Claruvis Pharmaceutical Co., Ltd. | NCT06783114 A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults | Upper Limb Spasticity | recruiting | 254 |
| 2026-09-30 est. | P2 | Beijing Anlong Biopharmaceutical Co., Ltd. | NCT06839339 Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD | Wet Age-related Macular Degeneration (wAMD) | not yet recruiting | 40 |
| 2026-09-30 | P3 | Vir Biotechnology, Inc. VIR | NCT06903338 A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Viral Hepatitis | active not recruiting | 124 |
| 2026-09-30 est. | P3 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT06958692 A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder | Major Depressive Disorder (MDD) | recruiting | 388 |
| 2026-09-30 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07000955 Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity | Obesity | active not recruiting | 98 |
| 2026-09-30 est. | P2 | Tarian Pharma | NCT07082764 Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy | Chemotherapy Induced Peripheral Neuropathy | not yet recruiting | 30 |
| 2026-09-30 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07124793 A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors | EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer | not yet recruiting | 60 |
| 2026-09-30 est. | P2 | Cerus Corporation CERS | NCT07155031 Biotin-Acridine Red Cell Exchange Kinetics | Sickle Cell Disease | withdrawn | |
| 2026-09-30 est. | P2 | Graegis Pharmaceuticals Ltd | NCT07192588 A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer | Radiodermatitis; Acute | active not recruiting | 273 |
| 2026-09-30 est. | P2 | Kahr Bio Australia Pty Ltd | NCT07235293 A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | Colorectal Cancer | recruiting | 90 |
| 2026-09-30 est. | P2 | Hebei Senlang Biotechnology Inc., Ltd. | NCT07244380 Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. | T Lymphoblastic Leukemia/Lymphoma | not yet recruiting | 38 |
| 2026-09-30 est. | P3 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | NCT07265284 A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis | Psoriasis | recruiting | 104 |
| 2026-09-30 est. | P2 | Shanghai Institute Of Biological Products | NCT07327398 Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above | Influenza | not yet recruiting | 1200 |
| 2026-09-30 | P2 | Kylonova (Xiamen) Biopharma co., LTD. | NCT07327840 Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a) | Lipoprotein Disorder | active not recruiting | 204 |
| 2026-09-30 est. | P2 | Joincare Pharmaceutical Group Industry Co., Ltd | NCT07351734 A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD | COPD (Chronic Obstructive Pulmonary Disease) | recruiting | 120 |
| 2026-09-30 est. | P3 | UpTru Inc. | NCT07356349 Study to Confirm the AuthenTicity of Point of Care Urine samplEs Using Oral fluoreScein Sodium in adulTs With substancE Use Disorder (ATTESTED) | Substance Use Disorder (SUD) | not yet recruiting | 114 |
| 2026-09-30 est. | P1/P2 | EveryONE Medicines Inc. | NCT07410143 Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) | Pediatric SDLT CNS Disorders | active not recruiting | 1 |
| 2026-09-30 est. | P2 | Akeso | NCT07436234 A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis | not yet recruiting | 111 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.